1,4-bis<<(6-methylpyrid-2-yl)amino>carbonyl>benzene | 129708-38-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,4-bis<<(6-methylpyrid-2-yl)amino>carbonyl>benzene
• 英文别名: 1-N,4-N-bis(6-methylpyridin-2-yl)benzene-1,4-dicarboxamide
• CAS: 129708-38-9
• 化学式: C₂₀H₁₈N₄O₂
• 分子量: 346.389
• InChiKey: PQXNYGMKOAGDNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  84
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,4-bis<<(6-methylpyrid-2-yl)amino>carbonyl>benzene 在 双氧水 作用下， 以 溶剂黄146 为溶剂， 反应 6.0h， 以38%的产率得到N-(6-Methyl-1-oxy-pyridin-2-yl)-N'-(6-methyl-pyridin-2-yl)-terephthalamide
  参考文献：
  名称：

  分子识别中的定向氢键抑制：NMR案例研究二羧酸与新型混合二酰胺受体（具有一个相邻的吡啶-N-氧化物）的氢键

  摘要：

  观察到新的具有酰胺-N-氧化物和与酰胺部分相邻的简单吡啶环的二酰胺受体1对己二酸识别中氢键形成的抑制作用。NMR研究表明，吡啶酰胺基团的结合力为1，这表明羧基和与吡啶相邻的酰胺与与吡啶N-氧化物相邻的另一酰胺之间的氢键键合有所区别。1与丙酸的NMR结合研究证实了氢在1中由两种不同的酰胺键结合到羧基上的特定抑制作用。

  DOI：

  10.1016/j.tetlet.2004.12.121
• 作为产物：
  描述：

  2-氨基-6-甲基吡啶 、 对苯二甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以75%的产率得到1,4-bis<<(6-methylpyrid-2-yl)amino>carbonyl>benzene
  参考文献：
  名称：

  Molecular recognition: a remarkably simple receptor for the selective complexation of dicarboxylic acids

  摘要：

  DOI：

  10.1021/ja00176a048

文献信息

• Anti-inflammatory medicaments
  申请人：Flynn Daniel L.

  公开号：US20080187978A1

  公开（公告）日：2008-08-07

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.

  提供了治疗炎症病症的新化合物及其使用方法。在一种首选实施例中，调节p38激酶蛋白的激活状态包括将该激酶蛋白与新化合物接触。
• Molecular recognition in the solid state: controlled assembly of hydrogen-bonded molecular sheets
  作者：Fernando Garcia-Tellado、Steven J. Geib、Shyamaprosad Goswami、Andrew D. Hamilton

  DOI：10.1021/ja00024a036

  日期：1991.11

  A novel hydrogen-bonding motif for the control of solid-state structures has been developed. The motif is based on the hydrogen bonding complementarity of carboxylic acids with 2-aminopyridine derivatives. Linking two aminopyridine groups through a rigid aromatic spacer provides a receptor unit that can complex dicarboxylic acids. When there is a good correspondence between the length of the spacer and that of the carboxylic acid, a discrete 1:1 complex is formed. When the dicarboxylic acid is longer than the receptor, an alternating hydrogen-bonded cocrystal occurs with the carboxylates on each diacid binding to different receptors. This motif dominates the cocrystal, forming even when the relative lengths of the diacid and the receptor change. Within the constraints of the alternating ribbon structure, the spatial position of the two components can be varied in a well-defined and predictable manner.
• HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY
  申请人：Wilks Angela

  公开号：US20100081661A1

  公开（公告）日：2010-04-01

  Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase.
• INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Serv

  公开号：US20190201414A1

  公开（公告）日：2019-07-04

  The present invention provides a method of preventing or treating a Mycobacterium tuberculosis (Mtb) infection in a mammal the method comprising administering to the mammal a first inhibitor, wherein the first inhibitor is an inhibitor of heme degradation and wherein the first inhibitor is a metal protoporphyrin, and administering to the mammal a second inhibitor, wherein the second inhibitor is an inhibitor of Mtb, wherein administration of the first and second inhibitors to the mammal prevents or treats Mtb infection in the mammal.
• US7202257B2
  申请人：——

  公开号：US7202257B2

  公开（公告）日：2007-04-10